{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T03:49:48Z","timestamp":1767152988142,"version":"build-2238731810"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2020,5,22]],"date-time":"2020-05-22T00:00:00Z","timestamp":1590105600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,5,22]],"date-time":"2020-05-22T00:00:00Z","timestamp":1590105600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1038\/s41409-020-0946-x","type":"journal-article","created":{"date-parts":[[2020,5,22]],"date-time":"2020-05-22T03:03:34Z","timestamp":1590116614000},"page":"2335-2338","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Idelalisib exposure before allogeneic stem cell transplantation in patients with follicular lymphoma: an EBMT survey"],"prefix":"10.1038","volume":"55","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7893-401X","authenticated-orcid":false,"given":"Leopold","family":"Sellner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2780-2981","authenticated-orcid":false,"given":"Johannes","family":"Schetelig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda","family":"Koster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Goda","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5684-9447","authenticated-orcid":false,"given":"Didier","family":"Blaise","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dietrich","family":"Beelen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabrizio Carnevale","family":"Schianca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jakob","family":"Passweg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Urs","family":"Schanz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanuel","family":"Gyan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federica","family":"Sora","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolaus","family":"Kr\u00f6ger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerald. G.","family":"Wulf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gwendolyn","family":"Van Gorkom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiri","family":"Mayer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corentin","family":"Orvain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean Henri","family":"Bourhis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8415-7069","authenticated-orcid":false,"given":"Pavel","family":"Jindra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victoria","family":"Potter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Zallio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabeth","family":"Vandenberghe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick J.","family":"Hayden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ibrahim","family":"Yakoub-Agha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Montoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Dreger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"on behalf of the European Society for Blood and Marrow Transplantation Lymphoma and Chronic Malignancies Working Parties","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,5,22]]},"reference":[{"key":"946_CR1","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1056\/NEJMoa1314583.","volume":"370","author":"AK Gopal","year":"2014","unstructured":"Gopal AK, Kahl BS, de Vos S, Wagner-Johnston ND, Schuster SJ, Jurczak WJ, et al. PI3Kdelta inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med. 2014;370:1008\u201318. https:\/\/doi.org\/10.1056\/NEJMoa1314583.","journal-title":"N Engl J Med"},{"key":"946_CR2","doi-asserted-by":"publisher","first-page":"e156","DOI":"10.3324\/haematol.2016.151738.","volume":"102","author":"G Salles","year":"2017","unstructured":"Salles G, Schuster SJ, de Vos S, Wagner-Johnston ND, Viardot A, Blum KA, et al. Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma: a subgroup analysis of a phase 2 study. Haematologica. 2017;102:e156\u2013e159. https:\/\/doi.org\/10.3324\/haematol.2016.151738.","journal-title":"Haematologica"},{"key":"946_CR3","doi-asserted-by":"publisher","unstructured":"Norman JE, Schouten HC, Dreger P, Robinson SP. The role of stem cell transplantation in the management of relapsed follicular lymphoma in the era of targeted therapies. Bone Marrow Transpl. 2018. https:\/\/doi.org\/10.1038\/s41409-018-0372-5.","DOI":"10.1038\/s41409-018-0372-5"},{"key":"946_CR4","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1002\/cncr.31264","volume":"124","author":"A Sureda","year":"2018","unstructured":"Sureda A, Zhang MJ, Dreger P, Carreras J, Fenske T, Finel H, et al. Allogeneic hematopoietic stem cell transplantation for relapsed follicular lymphoma: A combined analysis on behalf of the Lymphoma Working Party of the EBMT and the Lymphoma Committee of the CIBMTR. Cancer. 2018;124:1733\u201342.","journal-title":"Cancer"},{"key":"946_CR5","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1182\/blood-2016-03-707133.","volume":"128","author":"BL Lampson","year":"2016","unstructured":"Lampson BL, Kasar SN, Matos TR, Morgan EA, Rassenti L, Davids MS, et al. Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity. Blood. 2016;128:195\u2013203. https:\/\/doi.org\/10.1182\/blood-2016-03-707133.","journal-title":"Blood"},{"key":"946_CR6","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.1002\/cncr.30069.","volume":"122","author":"PA Thompson","year":"2016","unstructured":"Thompson PA, Stingo F, Keating MJ, Ferrajoli A, Burger JA, Wierda WG, et al. Outcomes of patients with chronic lymphocytic leukemia treated with first-line idelalisib plus rituximab after cessation of treatment for toxicity. Cancer. 2016;122:2505\u201311. https:\/\/doi.org\/10.1002\/cncr.30069.","journal-title":"Cancer"},{"key":"946_CR7","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1038\/bmt.2015.348.","volume":"51","author":"F Heinzelmann","year":"2016","unstructured":"Heinzelmann F, Bethge W, Beelen DW, Engelhard M, Kroger N, Dreger P, et al. Allogeneic hematopoietic cell transplantation as curative therapy for non-transformed follicular lymphomas. Bone Marrow Transpl. 2016;51:654\u201362. https:\/\/doi.org\/10.1038\/bmt.2015.348.","journal-title":"Bone Marrow Transpl"},{"key":"946_CR8","doi-asserted-by":"publisher","unstructured":"Robinson SP, Boumendil A, Finel H, Schouten H, Ehninger G, Maertens, J et al. Reduced intensity allogeneic stem cell transplantation for follicular lymphoma relapsing after an autologous transplant achieves durable long term disease control. An analysis from the Lymphoma Working Party of the EBMT. Ann Oncol. 2016. https:\/\/doi.org\/10.1093\/annonc\/mdw124.","DOI":"10.1093\/annonc\/mdw124"},{"key":"946_CR9","doi-asserted-by":"publisher","first-page":"5530","DOI":"10.1182\/blood-2008-01-136242.","volume":"111","author":"IF Khouri","year":"2008","unstructured":"Khouri IF, McLaughlin P, Saliba RM, Hosing C, Korbling M, Lee MS, et al. Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab. Blood. 2008;111:5530\u20136. https:\/\/doi.org\/10.1182\/blood-2008-01-136242.","journal-title":"Blood"},{"key":"946_CR10","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.3324\/haematol.2009.017608.","volume":"95","author":"JL Pinana","year":"2010","unstructured":"Pinana JL, Martino R, Gayoso J, Sureda A, de la Serna J, Diez-Martin JL, et al. Reduced intensity conditioning HLA identical sibling donor allogeneic stem cell transplantation for patients with follicular lymphoma: long-term follow-up from two prospective multicenter trials. Haematologica. 2010;95:1176\u201382. https:\/\/doi.org\/10.3324\/haematol.2009.017608.","journal-title":"Haematologica"},{"key":"946_CR11","doi-asserted-by":"publisher","first-page":"627","DOI":"10.3324\/haematol.10924","volume":"92","author":"S Vigouroux","year":"2007","unstructured":"Vigouroux S, Michallet M, Porcher R, Attal M, Ades L, Bernard M, et al. Long-term outcomes after reduced-intensity conditioning allogeneic stem cell transplantation for low-grade lymphoma: a survey by the French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC). Haematologica. 2007;92:627\u201334.","journal-title":"Haematologica"},{"key":"946_CR12","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1200\/JCO.2012.47.1862.","volume":"31","author":"R Pettengell","year":"2013","unstructured":"Pettengell R, Schmitz N, Gisselbrecht C, Smith G, Patton WN, Metzner B, et al. Rituximab purging and\/or maintenance in patients undergoing autologous transplantation for relapsed follicular lymphoma: a prospective randomized trial from the lymphoma working party of the European group for blood and marrow transplantation. J Clin Oncol. 2013;31:1624\u201330. https:\/\/doi.org\/10.1200\/JCO.2012.47.1862.","journal-title":"J Clin Oncol"},{"key":"946_CR13","doi-asserted-by":"publisher","first-page":"2510","DOI":"10.1182\/blood-2016-06-718106.","volume":"128","author":"CS Ujjani","year":"2016","unstructured":"Ujjani CS, Jung SH, Pitcher B, Martin P, Park SI, Blum KA, et al. Phase 1 trial of rituximab, lenalidomide, and ibrutinib in previously untreated follicular lymphoma: Alliance A051103. Blood. 2016;128:2510\u20136. https:\/\/doi.org\/10.1182\/blood-2016-06-718106.","journal-title":"Blood"},{"key":"946_CR14","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1200\/JCO.2016.70.4320.","volume":"35","author":"MS Davids","year":"2017","unstructured":"Davids MS, Roberts AW, Seymour JF, Pagel JM, Kahl BS, Wierda WG, et al. Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-Hodgkin lymphoma. J Clin Oncol. 2017;35:826\u201333. https:\/\/doi.org\/10.1200\/JCO.2016.70.4320.","journal-title":"J Clin Oncol"},{"key":"946_CR15","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1158\/2326-6066.CIR-14-0095.","volume":"2","author":"R Abu-Eid","year":"2014","unstructured":"Abu-Eid R, Samara RN, Ozbun L, Abdalla MY, Berzofsky JA, Friedman KM, et al. Selective inhibition of regulatory T cells by targeting the PI3K-Akt pathway. Cancer Immunol Res. 2014;2:1080\u20139. https:\/\/doi.org\/10.1158\/2326-6066.CIR-14-0095.","journal-title":"Cancer Immunol Res"}],"updated-by":[{"DOI":"10.1038\/s41409-021-01490-9","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,10,7]],"date-time":"2021-10-07T00:00:00Z","timestamp":1633564800000}}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41409-020-0946-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-020-0946-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-020-0946-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,8]],"date-time":"2021-10-08T08:46:06Z","timestamp":1633682766000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-020-0946-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,22]]},"references-count":15,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["946"],"URL":"https:\/\/doi.org\/10.1038\/s41409-020-0946-x","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,22]]},"assertion":[{"value":"15 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2021","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41409-021-01490-9","URL":"https:\/\/doi.org\/10.1038\/s41409-021-01490-9","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"EG: Honoraria and travel grants (Gilead). IY-A: Honoraria (Gilead). JS: Honoraria (Gilead\u2014Advisory Board and Lecture Fees). PJH: Honoraria (Amgen and Alnylam).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}